Arrowstreet Capital’s Cytek Biosciences CTKB Stock Holding History

Arrowstreet Capital’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$12.1M	Buy	2,036,660 +1,062,827	+109%	+$5.04M	0.01%	978
2026 Q2	$4.31M	Buy	973,833 +653,924	+204%	+$2.79M	﹤0.01%	1334
2026 Q1	$1.4M	Sell	319,909 -41,768	-12%	-$197K	﹤0.01%	1476
2025 Q4	$1.83M	Buy	361,677 +387	+0.1%	+$1.8K	﹤0.01%	1434
2025 Q3	$1.25M	Buy	361,290 +217,038	+150%	+$815K	﹤0.01%	1547
2025 Q2	$490K	Buy	144,252 +96,098	+200%	+$320K	﹤0.01%	1752
2025 Q1	$193K	Buy	+48,154	New	+$250K	﹤0.01%	1743

Other funds holding CTKB

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Boston Partners Boston, Massachusetts $111B AUM 30.48% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Royce & Associates New York $11B AUM 39.4% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return

Arrowstreet Capital's CTKB Position: Q3 2026 in Review

Arrowstreet Capital increased its Cytek Biosciences (CTKB) stake by 109% in Q3 2026, buying an estimated $5.04M and bringing the position to 2,036,660 shares worth $12.1M. The position accounts for 0.01% of the portfolio, ranked #978.

Arrowstreet Capital first reported a position in CTKB in Q1 2025 and has held it in 7 quarters since. 107 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.

Arrowstreet Capital held 2,036,660 shares of Cytek Biosciences worth $12.1M as of Q3 2026.
Arrowstreet Capital bought 1,062,827 Cytek Biosciences shares in Q3 2026, an estimated $5.04M.
Cytek Biosciences made up 0.01% of Arrowstreet Capital's portfolio in Q3 2026, its #978 holding.
Arrowstreet Capital first reported a position in Cytek Biosciences in Q1 2025 and has held it in 7 quarters since.
107 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.

Based on Arrowstreet Capital's 13F filing for Q3 2026, filed 13 Nov 2026.